Overview

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Status:
Completed

Trial end date:
2011-12-30

Target enrollment:

Participant gender:

Summary

The trial is designed to assess the safety and tolerability of TNX-102 2.4 mg and to compare the bio-availability of TNX-102 2.4 mg and cyclobenzaprine 5 mg tablets under fasting or fed conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Tonix Pharmaceuticals, Inc.

Treatments:

Amitriptyline
Cyclobenzaprine